An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment.
Level III
Where this comes from
- Record sourced from PubMed, PMID 32632160.
- Also identified by DOI 10.1038/s41467-020-17317-y and PMC identifier 7338506.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. To support decision making on the deployment of serology for either population screening or diagnostics, we present a detailed comparison of serological COVID-19 assays. We show that among the selected assays there is a wide diversity in assay performance in different scenarios and when correlated to virus neutralizing antibodies. The Wantai ELISA detecting total immunoglobulins against the receptor binding domain of SARS CoV-2, has the best overall characteristics to detect functional antibodies in different stages and severity of disease, including the potential to set a cut-off indicating the presence of protective antibodies. The large variety of available serological assays requires proper assay validation before deciding on deployment of assays for specific applications.
Medical subject headings
- Antibodies, Viral
- Coronavirus Infections
- Pneumonia, Viral
- Serologic Tests